Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 290-298

  Drinberg, Velthe ^a   Bitcover, Rivka ^a   Rajchenbach, Wolf ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer MDR; Nanomedicine; Sertraline; SSRI

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; SERTRALINE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; METABOLISM; OVARIAN NEOPLASMS; PROCEDURES; RANDOMIZATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; NANOMEDICINE; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; SERTRALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907979128     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.026     Document Type: Article

References (38)

1. World Health Organization (WHO), Cancer, Fact sheet N°297, Updated February 2014.
2. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
3. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
4. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem 1993, 62:385-427.
5. Peer D., Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett 2006, 237:180-187.
6. Ullah M.F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev 2008, 9:1-6.
7. Peer D., Dekel Y., Melikhov D., Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004, 64:7562-7569.
8. Bogart L.K., Pourroy G., Murphy C.J., Puntes V., Pellegrino T., Rosenblum D., et al. Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano 2014, 8:3107-3122.
9. Rosenblum D., Peer D. Omics-based nanomedicine: The future of personalized oncology. Cancer Lett 2014, 352:126-136.
10. Argov M., Kashi R., Peer D., Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 2009, 274:118-125.
11. Cookson J., Duffett R. Fluoxetine: therapeutic and undesirable effects. Hosp. Med 1998, 59:622-626.
12. Cohen K., Emmanuel R., Kisin-Finfer E., Shabat D., Peer D. Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 2014, 8:2183-2195.
13. Barenholz Y.C. Doxil® - the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
14. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
15. Mizrahy S., Goldsmith M., Leviatan-Ben-Arye S., Kisin-Finfer E., Redy O., Srinivasan S., et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014, 6:3742-3752.
16. Amselem S., Gabizon A., Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J. Pharm. Sci 1990, 79:1045-1052.
17. Zhang Y., Zhou T., Duan J., Xiao Z., Li G., Xu F. Inhibition of P-glycoprotein and glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells. Biomed. Pharmacother 2013, 67:757-762.
18. Barenholz Y., Peer D. Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. J. Control. Release 2012, 160:115-116.
19. Barenholz Y.C., Peer D. Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chem. Phys. Lipids 2012, 165:363-364.
20. Germann U.A., Ford P.J., Shlyakhter D., Mason V.S., Harding M.W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997, 8:141-155.
21. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci 2001, 58:931-959.
22. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001, 61:749-758.
23. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000, 60:2964-2972.
24. Shepard R.L., Cao J., Starling J.J., Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int. J. Cancer 2003, 103:121-125.
25. Chauvier D., Kegelaer G., Morjani H., Manfait M. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J. Pharm. Sci 2002, 91:1765-1775.
26. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004, 64:1242-1246.
27. Stein U., Lage H., Jordan A., Walther W., Bates S.E., Litman T., et al. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int. J. Cancer 2002, 97:751-760.
28. Abe T., Koike K., Ohga T., Kubo T., Wada M., Kohno K., et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br. J. Cancer 1995, 72:418-423.
29. Germann U.A., Shlyakhter D., Mason V.S., Zelle R.E., Duffy J.P., Galullo V., et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997, 8:125-140.
30. Minderman H., O'Loughlin K.L., Pendyala L., Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Can Res 2004, 10:1826-1834.
31. Rieger L., Rieger J., Winter S., Streffer J., Esser P., Dichgans J., et al. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Acta Neuropathol 2000, 99:555-562.
32. Amram S., Ganoth A., Tichon O., Peer D., Nachliel E., Gutman M., et al. Structural characterization of the drug translocation path of MRP1/ABCC1. Isr. J. Chem 2014, 10.1002/ijch.201300132.
33. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. U.S.A. 1987, 84:7735-7738.
34. Baggetto L.G., Dong M., Bernaud J., Espinosa L., Rigal D., Bonvallet R., et al. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem. Pharmacol 1998, 56:1219-1228.
35. Guns E.S., Denyssevych T., Dixon R., Bally M.B., Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093 - a new modulator of MDR in cancer chemotherapy. Eur. J. Drug Metab. Pharmacokinet 2002, 27:119-126.
36. Naito M., Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother. Pharmacol 1997, 40(Suppl.):S20-S24.
37. Flament M.F., Lane R.M., Zhu R., Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int. Clin. Psychopharmacol 1999, 14:259-275.
38. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.